YMAB has 36-month beta value of 0.75. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for YMAB is 33.18M, and currently, short sellers hold a 7.02% ratio of that float. The average trading volume of YMAB on May 08, 2024 was 366.14K shares.
YMAB) stock’s latest price update
The stock of Y-Mabs Therapeutics Inc (NASDAQ: YMAB) has decreased by -18.59 when compared to last closing price of 17.21. Despite this, the company has experienced a -15.04% fall in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-05-07 that Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.15 per share a year ago.
YMAB’s Market Performance
Y-Mabs Therapeutics Inc (YMAB) has seen a -15.04% fall in stock performance for the week, with a -0.43% decline in the past month and a 7.36% surge in the past quarter. The volatility ratio for the week is 5.67%, and the volatility levels for the past 30 days are at 5.64% for YMAB. The simple moving average for the past 20 days is -9.46% for YMAB’s stock, with a 49.84% simple moving average for the past 200 days.
Analysts’ Opinion of YMAB
Many brokerage firms have already submitted their reports for YMAB stocks, with Wedbush repeating the rating for YMAB by listing it as a “Outperform.” The predicted price for YMAB in the upcoming period, according to Wedbush is $13 based on the research report published on May 10, 2023 of the previous year 2023.
Morgan Stanley gave a rating of “Underweight” to YMAB, setting the target price at $4 in the report published on January 27th of the previous year.
YMAB Trading at -11.04% from the 50-Day Moving Average
After a stumble in the market that brought YMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.97% of loss for the given period.
Volatility was left at 5.64%, however, over the last 30 days, the volatility rate increased by 5.67%, as shares surge +6.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.97% lower at present.
During the last 5 trading sessions, YMAB fell by -10.92%, which changed the moving average for the period of 200-days by +134.29% in comparison to the 20-day moving average, which settled at $15.52. In addition, Y-Mabs Therapeutics Inc saw 105.43% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at YMAB starting from Gad Thomas, who sale 3,900 shares at the price of $16.44 back on Mar 05 ’24. After this action, Gad Thomas now owns 158,700 shares of Y-Mabs Therapeutics Inc, valued at $64,116 using the latest closing price.
Rajah Vignesh, the SVP & CHIEF MEDICAL OFFICER of Y-Mabs Therapeutics Inc, sale 1,711 shares at $16.53 during a trade that took place back on Mar 05 ’24, which means that Rajah Vignesh is holding 33,889 shares at $28,283 based on the most recent closing price.
Stock Fundamentals for YMAB
Current profitability levels for the company are sitting at:
- -0.3 for the present operating margin
- 0.89 for the gross margin
The net margin for Y-Mabs Therapeutics Inc stands at -0.26. The total capital return value is set at -0.24. Equity return is now at value -20.93, with -16.62 for asset returns.
Based on Y-Mabs Therapeutics Inc (YMAB), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -14.89. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -19.4.
Currently, EBITDA for the company is -20.45 million with net debt to EBITDA at 2.99. When we switch over and look at the enterprise to sales, we see a ratio of 6.38. The receivables turnover for the company is 4.1for trailing twelve months and the total asset turnover is 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.15.
Conclusion
To put it simply, Y-Mabs Therapeutics Inc (YMAB) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
